Literature DB >> 8891131

Presence of vancomycin-resistant enterococci in farm and pet animals.

L A Devriese1, M Ieven, H Goossens, P Vandamme, B Pot, J Hommez, F Haesebrouck.   

Abstract

Enterococcus faecium strains with vanA-mediated glycopeptide resistance were isolated by enrichment culture from the intestines and feces of several animal species, mainly horses and dogs (8% positive), chickens (7% positive), and pigs (6% positive). Other vanA-positive enterococcal strains were identified as E. durans in gallinaceous birds, E. faecalis in a horse, and E. gallinarum in a pheasant. Samples from pigeons, cage birds, and ruminants were negative. It was concluded that vancomycin resistance is widespread among isolates from farm and pet animals.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8891131      PMCID: PMC163520     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Vancomycin-resistant Enterococcus durans.

Authors:  L M Hall; H Y Chen; R J Williams
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

2.  Influence of oral glycopeptides on the fecal flora of human volunteers: selection of highly glycopeptide-resistant enterococci.

Authors:  P Van der Auwera; N Pensart; V Korten; B E Murray; R Leclercq
Journal:  J Infect Dis       Date:  1996-05       Impact factor: 5.226

Review 3.  Phenotypic identification of the genus Enterococcus and differentiation of phylogenetically distinct enterococcal species and species groups.

Authors:  L A Devriese; B Pot; M D Collins
Journal:  J Appl Bacteriol       Date:  1993-11

4.  Emergence of high-level resistance to glycopeptides in Enterococcus gallinarum and Enterococcus casseliflavus.

Authors:  S Dutka-Malen; B Blaimont; G Wauters; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

5.  Enterococcus faecium strains with vanA-mediated high-level glycopeptide resistance isolated from animal foodstuffs and fecal samples of humans in the community.

Authors:  I Klare; H Heier; H Claus; G Böhme; S Marin; G Seltmann; R Hakenbeck; V Antanassova; W Witte
Journal:  Microb Drug Resist       Date:  1995       Impact factor: 3.431

6.  Environmental strains of Enterococcus faecium with inducible high-level resistance to glycopeptides.

Authors:  I Klare; H Heier; H Claus; W Witte
Journal:  FEMS Microbiol Lett       Date:  1993-01-01       Impact factor: 2.742

7.  vanA-mediated vancomycin-resistant Enterococcus spp. in sewage.

Authors:  C Torres; J A Reguera; M J Sanmartin; J C Pérez-Díaz; F Baquero
Journal:  J Antimicrob Chemother       Date:  1994-03       Impact factor: 5.790

8.  Susceptibility of fecal streptococci of poultry origin to nine growth-promoting agents.

Authors:  G N Dutta; L A Devriese
Journal:  Appl Environ Microbiol       Date:  1982-10       Impact factor: 4.792

9.  Characterization of glycopeptide-resistant enterococci from U.S. hospitals.

Authors:  N C Clark; R C Cooksey; B C Hill; J M Swenson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

10.  Farm animals as a putative reservoir for vancomycin-resistant enterococcal infection in man.

Authors:  J Bates; J Z Jordens; D T Griffiths
Journal:  J Antimicrob Chemother       Date:  1994-10       Impact factor: 5.790

View more
  46 in total

1.  Development of a PCR assay for rapid detection of enterococci.

Authors:  D Ke; F J Picard; F Martineau; C Ménard; P H Roy; M Ouellette; M G Bergeron
Journal:  J Clin Microbiol       Date:  1999-11       Impact factor: 5.948

2.  Molecular epidemiology of vancomycin-resistant Enterococcus faecium in a large urban hospital over a 5-year period.

Authors:  W E Bischoff; T M Reynolds; G O Hall; R P Wenzel; M B Edmond
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

3.  Vancomycin-resistant Enterococcus faecium strains with highly similar pulsed-field gel electrophoresis patterns containing similar Tn1546-like elements isolated from a hospitalized patient and pigs in Denmark.

Authors:  L B Jensen; A M Hammerum; R L Poulsen; H Westh
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

Review 4.  What action should be taken to prevent spread of vancomycin resistant enterococci in European hospitals?

Authors:  Ben Ridwan; Ellen Mascini; Netty van Der Reijden; Jan Verhoef; Marc Bonten
Journal:  BMJ       Date:  2002-03-16

Review 5.  Vancomycin-resistant enterococci.

Authors:  Y Cetinkaya; P Falk; C G Mayhall
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

6.  From vanA Enterococcus hirae to vanA Enterococcus faecium: a study of feed supplementation with avoparcin and tylosin in young chickens.

Authors:  B Robredo; K V Singh; F Baquero; B E Murray; C Torres
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

7.  Dogs should be included in surveillance programs for vancomycin-resistant enterococci.

Authors:  Inmaculada A Herrero; Jose F Fernández-Garayzábal; Miguel A Moreno; Lucas Domínguez
Journal:  J Clin Microbiol       Date:  2004-03       Impact factor: 5.948

8.  Molecular diversity and evolutionary relationships of Tn1546-like elements in enterococci from humans and animals.

Authors:  R J Willems; J Top; N van den Braak; A van Belkum; D J Mevius; G Hendriks; M van Santen-Verheuvel; J D van Embden
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

9.  Enterococci with acquired vancomycin resistance in pigs and chickens of different age groups.

Authors:  P Butaye; L A Devriese; H Goossens; M Ieven; F Haesebrouck
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

10.  Characterization of a vancomycin-resistant Enterococcus faecalis (VREF) isolate from a dog with mastitis: further evidence of a clonal lineage of VREF in New Zealand.

Authors:  Janet M Manson; Stefanie Keis; John M B Smith; Gregory M Cook
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.